Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intuitive Surgical Inc ISRG

Intuitive Surgical, Inc. develops, manufactures, and markets the da Vinci surgical system and the Ion endoluminal system. The Company's products and related services enable physicians and healthcare providers to access minimally invasive care. The da Vinci surgical system consists of a surgeon console or consoles, a patient-side cart, and a high-performance vision system. The da Vinci products fall into five categories, namely da Vinci surgical systems, da Vinci instruments and accessories, da Vinci Stapling, da Vinci Energy, and da Vinci Vision, including Firefly Fluorescence imaging systems and da Vinci Endoscopes. It also provides a comprehensive suite of systems, learning, and services offerings. The Ion endoluminal system consists of a system cart, a controller, a catheter, and a vision probe. It extends its commercial offerings beyond surgery into diagnostic procedures, enabling minimally invasive biopsies in the lung. Both systems use software, instruments, and accessories.


NDAQ:ISRG - Post by User

Post by GoldenArmon Jul 20, 2022 12:12pm
126 Views
Post# 34837336

Strong move to upside

Strong move to upside
ahead of earnings. We bottomed out in my opinion and unless someone there had a massive brain fart or a stroke. They should beat estimates. Yes the cost of things have gone up and that effects contracts but new contracts will absorb a lot of the reduced earnings from decreased margins.

The stock is trading 47x trailing earnings. Unless hospital ICU get crowded we should see good growth. One sign is that the company has kept silent. My opinion is everyoen is busier that they were before which is a positive for revenue growth (a given) and hopefully better earnings than excepted by the street. We are a long was off $360 high but eventuall we should get back there with earnings growth. Good time to average down.
<< Previous
Bullboard Posts
Next >>